Development
Ocular Therapeutix, Inc.
OCUL
$8.18
-$0.15-1.80%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 58.44M | 57.72M | 54.60M | 51.68M | 51.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.44M | 57.72M | 54.60M | 51.68M | 51.49M |
| Cost of Revenue | 66.34M | 63.31M | 61.71M | 59.56M | 58.00M |
| Gross Profit | -7.89M | -5.59M | -7.11M | -7.88M | -6.51M |
| SG&A Expenses | 74.49M | 76.10M | 76.92M | 75.49M | 72.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.83M | 139.41M | 138.62M | 135.05M | 130.15M |
| Operating Income | -82.38M | -81.69M | -84.02M | -83.37M | -78.65M |
| Income Before Tax | -80.74M | -67.06M | -90.73M | -88.81M | -71.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.74 | -67.06 | -90.73 | -88.81 | -71.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.74M | -67.06M | -90.73M | -88.81M | -71.04M |
| EBIT | -82.38M | -81.69M | -84.02M | -83.37M | -78.65M |
| EBITDA | -79.40M | -79.18M | -81.89M | -81.34M | -76.55M |
| EPS Basic | -1.01 | -0.87 | -1.17 | -1.15 | -0.92 |
| Normalized Basic EPS | -0.74 | -0.65 | -0.73 | -0.72 | -0.58 |
| EPS Diluted | -1.26 | -1.15 | -1.21 | -1.19 | -1.02 |
| Normalized Diluted EPS | -0.73 | -0.64 | -0.72 | -0.70 | -0.55 |
| Average Basic Shares Outstanding | 319.24M | 311.82M | 309.42M | 308.14M | 307.50M |
| Average Diluted Shares Outstanding | 325.01M | 323.36M | 315.19M | 319.68M | 324.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |